Table 3.

Adverse Events.^*

Event	Solanezumab (N = 572)	Placebo (N = 591)
	number (percent)
Any adverse event	560 (97.9)	577 (97.6)
Adverse event definitely related to solanezumab or placebo†	6 (1.0)	8 (14)
Serious adverse event	172 (30.1)	158 (26.7)
Death	6 (1.0)	7 (12)
Adverse event leading to discontinuation of solanezumab or placebo	28 (4.9)	34 (5.8)
ARIA	167 (29.2)	194 (32.8)
ARIA with edema	1 (02)	2 (0.3)
ARIA with microhemorrhage or hemosiderosis	167 (29.2)	194 (32.8)
Microhemorrhage	158 (27.6)	189 (32.0)
Superficial siderosis	19 (3.3)	19 (3.2)

^*Shown are adverse events that emerged or worsened after the first dose of solanezumab or placebo. ARIA denotes amyloid-related imaging abnormalities.

^†The relatedness of the adverse event to solanezumab or placebo was determined by the site investigator.